AbbVie's Rinvoq gets EU nod for children with inflammatory disease
European Commission cleared AbbVie’s Rinvoq for active polyarticular juvenile idiopathic arthritis in patients aged 2 and older, targeting children who failed or cannot tolerate at least one DMARD. The decision relied on the open-label Phase 1 SELECT-YOUTH pediatric study.